Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at Wolfe Research Healthcare Conference (Virtual) Transcript

Nov 18, 2020 / 06:30PM GMT
Release Date Price: R$25.25 (-0.68%)
Timothy Minton Anderson
Wolfe Research, LLC - MD of Equity Research

Great. Okay. Well, thanks for joining us. I'm Tim Anderson, the large-cap pharma and biotech analyst at Wolfe Research. And for the next 30 or 35 minutes, we'll be talking with Josh Smiley, who is Senior Vice President and the CFO for Eli Lilly.

Since joining the company in 1995, he's held executive positions across finance and sales and marketing. His experience includes leading U.S. sales and marketing efforts to payers such as managed care organizations and Medicare and Medicaid. We're just going to jump straight into Q&A given the limited time.

Questions & Answers

Timothy Minton Anderson
Wolfe Research, LLC - MD of Equity Research

High-level questions first, just touching on health care reform. I know what the industry wants to see happen, which is things like a lower out-of-pocket spending and that sort of thing. But my question is really trying to understand what's likely to happen as the new administration takes over? So in that sense, asking you to kind of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot